ROME Therapeutics Company Profile

Background

Founded in April 2020, ROME Therapeutics is a biotechnology company dedicated to developing novel therapies for serious diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. The company's mission is to harness the power of the repeatome—the approximately 60% of the human genome consisting of repetitive sequences, often referred to as the "dark genome"—to discover and develop breakthrough medicines. By focusing on this largely unexplored genomic territory, ROME aims to address unmet medical needs and transform the treatment landscape for various diseases.

Key Strategic Focus

ROME's strategic focus centers on leveraging its proprietary data science platform to identify and target disease-relevant consequences of repeat element dysregulation. The company specializes in three primary areas:

• Viral Mimicry: Developing therapeutics that block repeat-induced proinflammatory responses.

• Tumor Antigens: Creating treatments that specifically target cancer cells expressing abnormally high levels of repeat-derived antigens.

• Genomic Instability: Designing therapies to address repeat-induced genomic instability associated with disease.

By focusing on these areas, ROME aims to develop first-in-class therapeutics that modulate disease at its source, offering potential disease-modifying treatments for patients.

Financials and Funding

Since its inception, ROME Therapeutics has successfully secured substantial funding to support its research and development initiatives:

• Series A Financing (April 2020): Raised $50 million, led by GV and ARCH Venture Partners, with participation from Partners Innovation Fund.

• Series B Financing (September 2021): Secured $77 million, led by Section 32, with new investors including Sanofi Ventures, Casdin Capital, Andreessen Horowitz, and Alexandria Venture Investments, alongside existing investors.

• Series B Extension (September 2023): Completed an oversubscribed $72 million extension, bringing the total Series B amount to $149 million. New investors included Johnson & Johnson Innovation-JJDC, Bristol Myers Squibb, Eurofarma Ventures, Luma Group, Mirae Asset Capital, and family offices Raycap and Sigmas Group.

The capital raised is intended to advance ROME's lead program into clinical trials, expand its pipeline of repeatome-derived programs, and enhance its proprietary data science platform.

Pipeline Development

ROME's pipeline is focused on developing therapies that target the consequences of repeat element dysregulation:

• Lead Program: An inhibitor of LINE-1 reverse transcriptase (RT), aimed at treating autoimmune diseases such as lupus. This program is progressing into early clinical trials, including Phase 1 studies to evaluate safety and determine optimal dosing.

• Additional Programs: ROME is advancing several other programs targeting autoimmune diseases, cancer, and neurodegeneration, leveraging its data science platform to identify and develop first-in-class therapeutic opportunities.

Technological Platform and Innovation

ROME's proprietary data science platform is central to its innovative approach:

• Proprietary Technologies: The platform utilizes advanced algorithms and machine learning methods to map and annotate functionally active repeat elements within the dark genome.

• Scientific Methodologies: High-resolution mapping techniques identify active repeats, while machine learning quantifies their expression to determine their role in disease.

This platform supports target discovery, indication selection, clinical trial design, biomarker discovery, and potentially measures individual patient responses to therapies.

Leadership Team

ROME Therapeutics is led by a team of experienced professionals:

• Rosana Kapeller, M.D., Ph.D. – President, Chief Executive Officer, and Co-founder. Dr. Kapeller previously served as founding Chief Scientific Officer at Nimbus Therapeutics, where she led the development of novel therapeutics using advanced computational technologies.

• David Ting, M.D. – Co-founder. Dr. Ting is the Associate Clinical Director for Innovation at the Massachusetts General Hospital Cancer Center and an Assistant Professor at Harvard Medical School, focusing on RNA expression patterns in cancer.

• Benjamin Greenbaum, Ph.D. – Co-founder. Dr. Greenbaum is an Associate Member of Memorial Sloan Kettering Cancer Center, specializing in computational oncology and the interaction of tumors with the immune system.

Leadership Changes

In September 2021, ROME expanded its Board of Directors with the appointments of:

• Steven J. Kafka, Ph.D. – Managing Partner at Section 32. Dr. Kafka brings extensive experience in venture capital and biotechnology leadership.

• Jim Trenkle, Ph.D. – Head of Investments at Sanofi Ventures. Dr. Trenkle has a background in research and development, commercialization, and early-stage biotech investing.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in oncology and immunology, is highly competitive and rapidly evolving. The global oncology market was valued at approximately $150 billion in 2022, with projections estimating growth to about $267 billion by 2027. This growth is driven by continuous innovation and the development of novel therapies.

Competitor Analysis

ROME Therapeutics faces competition from established biotech companies with advanced pipelines and substantial resources:

• Amgen: A leading biotechnology company with a diverse portfolio in oncology and immunology.

• Genentech: Known for its innovative cancer therapies and strong research capabilities.

• Novartis: A global pharmaceutical company with significant investments in oncology and autoimmune disease treatments.

These competitors have established market positions and extensive resources, posing challenges for emerging companies like ROME.

Strategic Collaborations and Partnerships

ROME Therapeutics has established strategic partnerships to enhance its research and development efforts:

• Academic and Research Institutions: Collaborations with institutions such as Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center provide access to cutting-edge research and expertise.

• Biopharmaceutical Companies: Partnerships with companies like Sanofi Ventures and Bristol Myers Squibb offer funding, resources, and industry expertise to advance ROME's pipeline.

• Technology Partnerships: Collaborations with technology companies provide innovative tools and platforms for drug discovery and development.

These partnerships are integral to ROME's strategy, enabling the company to leverage collective expertise and resources to accelerate the translation of scientific discoveries into therapeutic solutions.

Operational Insights

ROME Therapeutics operates in a competitive landscape with several strategic considerations:

• Supplier Bargaining Power: The company relies on specialized suppliers for critical raw materials and advanced research tools, which can lead to high switching costs and dependence on a limited number of suppliers.

• Customer Bargaining Power: With a growing demand for innovative therapies, customers, including hospitals and research institutions, have increased expectations and access to alternative treatments, influencing pricing and adoption rates.

• Competitive Rivalry: The presence of numerous biotech companies targeting similar diseases drives intense competition, necessitating continuous innovation and strategic positioning.

Strategic Opportunities and Future Directions

ROME Therapeutics is poised to capitalize on several strategic opportunities:

• Expansion into Neurodegenerative Diseases: Leveraging preclinical data on LINE-1 RT inhibitors to address conditions like Parkinson's disease, representing a high unmet medical need.

• Advancements in Genomic Technologies: Utilizing long-read sequencing and machine learning to enhance understanding of the repeatome, accelerating target discovery and drug development.

• Strategic Partnerships: Forming alliances with established pharmaceutical companies and research institutions to access resources, share risks, and expedite therapy commercialization.